DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Plenvu is a drug marketed by Salix and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and seven patent family members in thirty-five countries.
The generic ingredient in PLENVU is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for PLENVU
Recent Clinical Trials for PLENVU
Identify potential brand extensions & 505(b)(2) entrants
|Istituto Clinico Humanitas||Phase 4|
|Quotient Clinical||Phase 1|
Recent Litigation for PLENVU
Identify potential future generic entrants
District Court Litigation
|BAUSCH HEALTH IRELAND LIMITED v. LUPIN INC.||2019-04-01|
|Bausch Health Ireland Limited v. Lupin Ltd.|
Paragraph IV (Patent) Challenges for PLENVU
|PLENVU||FOR SOLUTION;ORAL||ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate||209381||2018-12-06|
|Country||Patent Number||Estimated Expiration|
|Eurasian Patent Organization||027526||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|